# US 2012/0252113 A1 · Use of triplex structure dna in transferring nucleotide sequences

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252113 A1
- Document ID: US20120252113A1
- Status: Published application
- Kind: A1
- Application number: 13/238,133
- Filed: 2011-09-21
- Published: 2012-10-04
- Earliest claimed: 1998-04-24
- Assignees: Institut Pasteur; Institut National de la Sante et de la Recherche Medicale; Centre National De La Recherche Scientifique
- Inventors: Pierre Charneau; Véronique Zennou; Hüseyin Firat
- Web page: https://patentgrep.com/patent/US20120252113A1

## CPC

- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/51: {comprising whole cells, viruses or DNA/RNA}
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2740/16062: by genetic engineering
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- C12N 2840/20: translation of more than one cistron
- C12N 2840/203: having an IRES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention concerns a recombinant vector characterized in that it comprises a polynucleotide comprising a central initiation cis-active region (cPPT) and a termination cis-active region (CTS), the regions being of retroviral or retroviral-like origin, and the vector further comprising a predetermined nucleotide sequence (transgene or nucleotide sequence of interest) and retrotranscription regulating, expressing, and packaging signals of retroviral or retroviral-like origin.

## Claims

### Claim at position 1

1-40. (canceled)

### Claim 41

A method for generating recombinant lentiviral vector particles comprising transcomplementing a replication-deficient lentiviral vector with Gag, Pol, and Env proteins to generate recombinant lentiviral vector particles comprising the replication-deficient lentiviral vector;
wherein the replication-deficient lentiviral vector comprises a transgene, a lentiviral cis-acting central initiation region, and a lentiviral cis-acting termination region, such that a triplex DNA is formed during reverse transcription,
wherein the triplex DNA stimulates the nuclear import of the transgene into the nucleus of a cell transduced with said vector; and
wherein the replication-deficient lentiviral vector does not encode functional Gag, Pol, and Env proteins.

### Claim 42 (depends on 41)

The method of claim 41, wherein the cis-acting central initiation region and the cis-acting termination region are derived from a human immunodeficiency virus type 1 genome.

### Claim 43 (depends on 41)

The method of claim 41, wherein the Gag protein is a human immunodeficiency virus type 1 Gag protein.

### Claim 44 (depends on 41)

The method of claim 41, wherein Pol protein is a human immunodeficiency virus type 1 Pol protein.

### Claim 45 (depends on 43)

The method of claim 43, wherein Pol protein is a human immunodeficiency virus type 1 Pol protein.

### Claim 46 (depends on 41)

The method of claim 41, wherein the Env protein is a human immunodeficiency virus type 1 Env protein.

### Claim 47 (depends on 43)

The method of claim 43, wherein the Env protein is a human immunodeficiency virus type 1 Env protein.

### Claim 48 (depends on 45)

The method of claim 45, wherein the Env protein is a human immunodeficiency virus type 1 Env protein.

### Claim 49 (depends on 41)

The method of claim 41, wherein the Env protein is a vesicular somatitis virus Env protein.

### Claim 50 (depends on 43)

The method of claim 43, wherein the Env protein is a vesicular somatitis virus Env protein.

### Claim 51 (depends on 45)

The method of claim 45, wherein the Env protein is a vesicular somatitis virus Env protein.

### Claim 52 (depends on 42)

The method of claim 42, wherein the Gag protein is a human immunodeficiency virus type 1 Gag protein.

### Claim 53 (depends on 42)

The method of claim 42, wherein Pol protein is a human immunodeficiency virus type 1 Pol protein.

### Claim 54 (depends on 52)

The method of claim 52, wherein Pol protein is a human immunodeficiency virus type 1 Pol protein.

### Claim 55 (depends on 42)

The method of claim 42, wherein the Env protein is a human immunodeficiency virus type 1 Env protein.

### Claim 56 (depends on 52)

The method of claim 52, wherein the Env protein is a human immunodeficiency virus type 1 Env protein.

### Claim 57 (depends on 54)

The method of claim 54, wherein the Env protein is a human immunodeficiency virus type 1 Env protein.

### Claim 58 (depends on 42)

The method of claim 42, wherein the Env protein is a vesicular somatitis virus Env protein.

### Claim 59 (depends on 52)

The method of claim 52, wherein the Env protein is a vesicular somatitis virus Env protein.

### Claim 60 (depends on 54)

The method of claim 54, wherein the Env protein is a vesicular somatitis virus Env protein.
